Your session is about to expire
← Back to Search
Sitagliptin for Type 2 Diabetes with Genetic Mutation
Study Summary
This trial is testing whether a DPP4 inhibitor can help people with a specific gene mutation by reducing DPP4 activity and glucose levels.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is it plausible to join this trial?
"This research project is seeking 20 participants with a genetic disorder, aged between 18 and 80. To be eligible, individuals must meet the following criteria: Cases are classed as adults from 18-70 years old that likely possess weakened DPP4., Controls should match cases in terms of age, gender, ethnicity, BMI measurements, hypertension status, diabetes symptoms , renal function levels and any drugs used which may alter outcomes of interest., Lastly all applicants need to have consented for their records to be saved on Penn Medicine Biobank so they can potentially partake in future studies."
What is the participant quota for this medical investigation?
"Yes, according to clinicaltrials.gov, this medical trial is actively recruiting patients with the original posting date being August 26th 2020 and most recent update on December 30th 2021. The study will incorporate a total of 20 participants from one site."
Is the study open to individuals aged sixty and above?
"This clinical trial has a minimum age requirement of 18 years old, while the upper limit is set at 80."
Are individuals eligible to participate in the current iteration of this research?
"Clinicaltrials.gov displays that this trial is currently enrolling patients, with its initial posting occurring on August 26th 2020 and the most recent update occurring on December 30th 2021."
Has this medicine been officially sanctioned by the government?
"Owing to the nature of this Phase 4 trial, our team at Power rated its safety as a 3 - indicating that it is an approved treatment."
Share this study with friends
Copy Link
Messenger